Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib

As the ICER fell within the cost per QALY range for many other widely used oncology medicines, everolimus is projected to be a cost-effective treatment relative to sorafenib for sunitinib-refractory mRCC.